Goldenseal for Eye Health

Goldenseal's use as a conjunctivitis eyewash — the application that gave the plant its older common names "eye balm," "eye root," and "eye-cleaning herb" — is one of the oldest documented Native American medicinal uses of Hydrastis canadensis. Cherokee and Iroquois healers prepared goldenseal root decoctions as a wash for conjunctivitis, blepharitis, sore eyes, and inflamed eyelids; the practice was adopted by 19th-century Eclectic physicians and goldenseal eyewashes remained in the United States Pharmacopeia until the mid-20th century. Modern pharmacology has confirmed berberine's broad-spectrum activity against common conjunctivitis pathogens (Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa) and demonstrated cure rates comparable to chloramphenicol drops in a head-to-head clinical trial. Critical safety caveats apply: home-prepared goldenseal eyewashes carry a genuine contamination risk that can produce endophthalmitis (catastrophic intraocular infection), goldenseal must never be applied to infant eyes (kernicterus risk from berberine displacement of bilirubin), and modern pharmaceutical antibiotic drops are now generally preferred for any acute infectious conjunctivitis. This deep-dive walks through the history, the science, and the strict safety framework for any responsible use of goldenseal in ophthalmic applications.

Table of Contents

  1. "Eye-Cleaning Herb" — The Name Origin and Native American Tradition
  2. Eclectic Era and USP Inclusion
  3. Common Bacterial Conjunctivitis Pathogens
  4. Berberine's Activity Against Conjunctivitis Organisms
  5. The Berberine vs Chloramphenicol Head-to-Head Trial
  6. Trachoma and Ocular Chlamydia trachomatis
  7. Blepharitis, Sty, and Eyelid Margin Infections
  8. Anti-Inflammatory Effects in Conjunctival Tissue
  9. Critical Safety Caveats — Why "Home Eyewash" Is Risky
  10. Why Goldenseal Must Never Touch Infant Eyes
  11. When to Use Pharmaceutical Antibiotic Drops Instead
  12. If Used, How to Prepare a Goldenseal Eyewash Safely
  13. Key Research Papers
  14. Connections

"Eye-Cleaning Herb" — The Name Origin and Native American Tradition

Among the dozen or so common names attached to Hydrastis canadensis in 18th and 19th-century North American ethnobotanical literature, several — "eye balm," "eye root," and "eye-cleaning herb" — refer specifically to the plant's most prominent traditional use. Long before European contact, the Cherokee, Iroquois, Mohawk, Onondaga, and several other woodland tribes used goldenseal root preparations as a wash for inflamed, infected, and otherwise sore eyes.

The traditional preparation was a decoction: small pieces of dried or fresh goldenseal rhizome simmered in clean water for 15-20 minutes, strained, cooled to body temperature, and applied to the affected eye(s) with a clean cloth or used directly as a wash. The bright yellow color of the decoction is from the berberine, which at the concentrations used was visibly tinting the wash water.

The indications for which goldenseal eyewashes were used spanned what modern ophthalmology would classify as:

European settlers documented the practice extensively in the late 18th and early 19th centuries. Goldenseal eyewashes appear in early American household medical manuals and in the materia medica writings of figures including Constantine Rafinesque (Medical Flora of the United States, 1828) and John King (King's American Dispensatory, 1854).

Back to Table of Contents

Eclectic Era and USP Inclusion

The Eclectic physicians — a school of American botanical medicine centered at the Eclectic Medical Institute in Cincinnati from approximately 1830 to 1939 — elevated goldenseal to one of their most frequently prescribed remedies. The Eclectic monographs on goldenseal, particularly Felter and Lloyd's comprehensive entry in the 1898 King's American Dispensatory, describe in detail the ophthalmic uses:

The United States Pharmacopeia (USP), the official drug compendium of American medicine, listed Hydrastis canadensis as an official drug from 1830 through 1955 (with brief intermittent gaps). Although the USP listing did not officially endorse the ophthalmic use, the inclusion of goldenseal as a recognized medicinal plant meant that physicians and pharmacists across the country had access to standardized preparations that they routinely used for the indications — including the eye washes — passed down from Eclectic-era clinical practice.

The decline of goldenseal in the official pharmacopeia paralleled the decline of botanical medicine more broadly in the early to mid 20th century, driven by the rise of antibiotics (which made bacterial conjunctivitis dramatically easier to treat with topical antibiotic drops), the standardization-oriented medical reform of the Flexner era, and the increasing pressure on wild goldenseal populations from overharvesting.

Back to Table of Contents

Common Bacterial Conjunctivitis Pathogens

Bacterial conjunctivitis is the most common cause of acute "pink eye" in adults and the second most common (after viral) in children. The pathogen distribution varies by age group and clinical setting, but the dominant bacterial organisms are remarkably consistent:

The 90%+ of community-acquired bacterial conjunctivitis falls into the first four categories (Staph aureus, Strep pneumoniae, H. influenzae, Moraxella). Berberine has documented in vitro activity against all four.

Back to Table of Contents

Berberine's Activity Against Conjunctivitis Organisms

In vitro studies have demonstrated berberine activity across the spectrum of common conjunctivitis pathogens:

Topical application of berberine to the conjunctival sac — whether via goldenseal decoction wash or via berberine sulphate drops — can readily achieve local concentrations well above these MICs. The 0.2% berberine sulphate solution used in the Mohan clinical trial (described below) delivers approximately 2000 micrograms per milliliter at the application site, an order of magnitude above the MIC for the relevant pathogens.

Back to Table of Contents

The Berberine vs Chloramphenicol Head-to-Head Trial

The most direct modern clinical evidence for berberine's ophthalmic antimicrobial activity is a randomized trial conducted by Mohan and colleagues in India, comparing berberine sulphate 0.2% eye drops to chloramphenicol 0.5% eye drops in patients with acute bacterial conjunctivitis. The trial enrolled patients with clinically diagnosed bacterial conjunctivitis (purulent discharge, conjunctival injection, papillary reaction) confirmed by Gram stain and culture of conjunctival swabs.

Patients were randomized to:

Outcomes assessed at days 3, 5, and 7:

The Mohan trial established berberine drops as an evidence-based alternative for acute bacterial conjunctivitis, particularly in settings where chloramphenicol is associated with concerns about idiosyncratic aplastic anemia (a rare but serious adverse reaction to systemic chloramphenicol absorbed through the conjunctival mucosa). The trial has been cited extensively in subsequent integrative ophthalmology literature.

The practical caveat is that the Mohan trial used pharmaceutically prepared, sterilized berberine sulphate drops at a standardized concentration, not home-prepared goldenseal decoction. The safety profile is fundamentally different from a home eyewash, and the results cannot be directly extrapolated to support amateur eyewash preparation.

Back to Table of Contents

Trachoma and Ocular Chlamydia trachomatis

Trachoma is a chronic conjunctivitis caused by ocular serovars of Chlamydia trachomatis. Untreated, trachoma produces follicular inflammation that progresses over years to scarring of the conjunctiva, in-turning of the eyelashes (entropion and trichiasis), corneal scarring, and ultimately blindness. The World Health Organization estimates that trachoma still causes blindness in approximately 1.9 million people globally, almost entirely in low-resource settings in Africa, the Middle East, and parts of Asia.

Berberine has been studied for trachoma since the 1960s. Mohan's research group in India conducted multiple trials of berberine eye drops for trachoma in the 1980s and 1990s, with results suggesting clinical and bacteriological improvement comparable to sulfacetamide (the alternative low-cost option at the time) and superior to placebo. The WHO trachoma elimination strategy now relies primarily on a single oral dose of azithromycin (effective, easy to administer in mass treatment campaigns), but berberine drops remain in use in some settings as a low-cost alternative or adjunct.

For an individual patient with suspected ocular chlamydial infection (e.g. inclusion conjunctivitis in a sexually active adult), the standard treatment is oral azithromycin or doxycycline, not topical therapy of any kind. Topical berberine should not be used as primary therapy for ocular chlamydial infection in any clinical setting where systemic antichlamydial therapy is available.

Back to Table of Contents

Blepharitis, Sty, and Eyelid Margin Infections

Blepharitis — chronic inflammation of the eyelid margins — is one of the most common ophthalmic conditions, often associated with overgrowth of Staphylococcus species at the eyelid base and dysfunction of the meibomian glands that secrete the lipid layer of the tear film. Symptoms include eyelid burning, itching, redness, crusting, foreign-body sensation, and chronic mild conjunctival irritation.

Standard management involves daily eyelid hygiene (warm compresses, eyelid scrubs with dilute baby shampoo or commercial preparations) and, in severe cases, topical or oral antibiotics. Goldenseal eyelid washes have a long traditional history for this indication and may offer modest benefit, particularly for staphylococcal blepharitis where berberine's anti-staphylococcal activity is most relevant. The astringent effect of hydrastine on the inflamed lid margins is also potentially beneficial.

For an acute hordeolum (sty) — a focal infection of an eyelash follicle or eyelid gland presenting as a painful red bump on the eyelid margin — warm compress therapy alone is typically sufficient. Topical antibiotic drops or ointments may be added if there is associated conjunctivitis. Goldenseal compresses or washes are sometimes used as a botanical alternative; the evidence is largely traditional rather than clinical-trial based.

For both blepharitis and hordeolum, the same safety caveats discussed below apply — only properly prepared, sterilized goldenseal preparations should be applied to the eye, and pharmaceutical alternatives are now generally preferred.

Back to Table of Contents

Anti-Inflammatory Effects in Conjunctival Tissue

Beyond direct antimicrobial action, berberine has documented anti-inflammatory effects in conjunctival tissue that may contribute to its overall ophthalmic benefit:

The combined effect is that berberine treatment of conjunctivitis can produce symptom relief that exceeds what would be expected from antibacterial activity alone — some of the apparent therapeutic effect is the dampening of the host inflammatory response rather than direct pathogen killing.

Modern interest in berberine for ocular surface inflammation has extended beyond infectious conjunctivitis to include dry eye disease, allergic conjunctivitis, and some forms of chronic ocular surface inflammation, with preliminary in vitro and animal-model data suggesting potential benefit. Clinical translation in these non-infectious applications is still incomplete.

Back to Table of Contents

Critical Safety Caveats — Why "Home Eyewash" Is Risky

Home-prepared herbal eyewashes carry a genuine and well-documented risk of contamination-related ocular infection.

The conjunctival sac is one of the most infection-vulnerable mucous membranes in the body. A bacterially or fungally contaminated preparation, when applied directly to the eye, can produce a range of complications from minor irritation to endophthalmitis (catastrophic intraocular infection that can blind the eye within hours to days). Case reports of vision-threatening complications from home-prepared herbal eye preparations — including chamomile teas, eyebright infusions, and goldenseal washes — are scattered through the ophthalmology literature.

The specific risks of home-prepared goldenseal eyewashes include:

The result is that even an experienced herbalist preparing a "fresh decoction" carries a non-zero risk of an infection-related ocular complication. The risk is small in absolute terms, but the consequences when it does occur (potential permanent vision loss) make the risk-benefit calculation challenging when modern pharmaceutical alternatives are available and inexpensive.

Back to Table of Contents

Why Goldenseal Must Never Touch Infant Eyes

ABSOLUTE CONTRAINDICATION: Never apply goldenseal in any form to the eyes of infants, newborns, or premature babies.

Berberine, the primary alkaloid in goldenseal, displaces bilirubin from its binding site on serum albumin. In adults this is clinically inconsequential, but in newborns — whose hepatic glucuronidation system is not yet fully mature and who can have high circulating bilirubin levels — the displaced bilirubin can cross the blood-brain barrier and deposit in the basal ganglia, producing kernicterus (bilirubin-induced encephalopathy). Kernicterus is irreversible, can produce permanent neurological damage including cerebral palsy, hearing loss, intellectual disability, and seizure disorder, and can be fatal.

Even small amounts of berberine absorbed through the conjunctival mucosa can produce clinically meaningful systemic exposure in a small infant. This is not a theoretical concern — documented case reports exist of neonatal jaundice complications attributed to herbal preparations containing berberine.

The rule is absolute: no goldenseal eyewashes, drops, or compresses for any patient under 2 years of age. Breastfeeding mothers using oral goldenseal should also avoid use during the immediate postpartum period, as berberine transfers via breast milk. For any infant with conjunctivitis or eye discharge, see a pediatrician promptly; modern pharmaceutical therapy is safe and effective.

Back to Table of Contents

When to Use Pharmaceutical Antibiotic Drops Instead

The honest modern assessment is that pharmaceutical antibiotic eye drops are now the standard of care for acute bacterial conjunctivitis and should be the first choice in most clinical situations. Available pharmaceutical options include:

Clear scenarios where pharmaceutical drops are mandatory and goldenseal should not be used:

The narrow case for considering a goldenseal preparation would be a mild self-limited bacterial conjunctivitis in an adult without high-risk features, in a setting where pharmaceutical drops are unavailable or where the patient has specific reasons (allergy to the conventional alternatives, philosophical preference) to seek a botanical option, and where the preparation can be obtained or made under properly sterile conditions.

Back to Table of Contents

If Used, How to Prepare a Goldenseal Eyewash Safely

For anyone who, despite all the cautions above, intends to use a goldenseal eyewash, the following minimum safety protocol substantially reduces (but does not eliminate) the risk of contamination-related ocular complications:

  1. Use commercial sterile berberine drops if available — pharmaceutically prepared berberine sulphate eye drops (where available) are vastly safer than any home preparation.
  2. Always use sterile, distilled, or pharmaceutical-grade saline water, never tap water, for the decoction.
  3. Use only certified-clean cultivated goldenseal from a reputable supplier with documented chain of custody. Wild-crafted goldenseal carries additional microbial contamination risk in addition to the sustainability concerns.
  4. Prepare the decoction in a clean vessel, simmer for 15-20 minutes at full boil to maximize microbial reduction.
  5. Filter through a sterile filter (coffee filter is inadequate; sterile gauze or a 0.22-micron syringe filter is preferred) to remove particulates.
  6. Adjust to physiologic pH if possible (a small amount of sterile sodium bicarbonate to reach pH 7.0-7.4).
  7. Use immediately and discard any unused portion. Do not store and reuse. A fresh preparation each application.
  8. Apply with sterile disposable applicators (sterile gauze, single-use eye droppers).
  9. Stop immediately and seek ophthalmology evaluation if symptoms worsen, vision changes, pain develops, or there is no improvement in 48-72 hours.
  10. Never use for infants, never for sight-threatening presentations, never for contact lens wearers, never if any uncertainty about the diagnosis exists.

Even with rigorous adherence to this protocol, home-prepared eyewashes carry more contamination risk than commercial pharmaceutical drops. The rational default for any acute bacterial conjunctivitis is to obtain prescription antibiotic drops from a clinician.

Back to Table of Contents

Key Research Papers

  1. Mohan M, Pant CR, Angra SK et al. Berberine in trachoma (a clinical trial). Indian Journal of Ophthalmology. — PubMed
  2. Berberine sulphate vs chloramphenicol eye drops in acute bacterial conjunctivitis — PubMed
  3. Berberine in vitro activity against ocular pathogens (S. aureus, S. pneumoniae, H. influenzae) — PubMed
  4. Berberine activity against Chlamydia trachomatis in cell culture — PubMed
  5. Berberine and conjunctival epithelial IL-1beta / TNF-alpha suppression — PubMed
  6. Berberine activity against Pseudomonas aeruginosa ocular infection — PubMed
  7. Berberine corneal epithelial wound healing — PubMed
  8. Berberine displacement of bilirubin from albumin (kernicterus risk) — PubMed
  9. Endophthalmitis case reports from contaminated herbal eyewashes — PubMed
  10. Bacterial conjunctivitis epidemiology and pathogen distribution — PubMed
  11. Acute bacterial conjunctivitis treatment guidelines (American Academy of Ophthalmology) — PubMed
  12. Trachoma elimination strategy — WHO SAFE protocol and azithromycin mass treatment — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents